In an immunohistochemical analysis of pretreatment biopsy specimens from several tumor types, tumor cell-surface expression of PD-L1 was significantly correlated with an objective clinical response to nivolumab monotherapy in a dose-ranging phase I study [11]. The gene discussed is CD274; the disease is neoplasm.